Federal Register / Vol. 65, No. 28 / Thursday, February 10, 2000 / Notices 6613

If you have questions after reviewing

the contents of all documents, business

management technical assistance may

be obtained from: Mattie B. Jackson,

Grants Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Centers for Disease

Control and Prevention (CDC), 2920

Brandywine Road, Room 3000, Atlanta,

GA 30341–4146, telephone (770) 488–

2718, Internet address mij3.@cdc.gov

For programmatic technical

assistance, contact: Claudette A. GrantJoseph, Chief, Program Services Section,

Lead Poisoning Prevention Branch,

Division of Environmental Hazards and

Health Effects, National Center for

Environmental Health, Centers for

Disease Control and Prevention (CDC),

1600 Clifton Road, NE, Mailstop E–25,

Atlanta, GA 30333, telephone (404)

639–2510, Internet address

cag4@cdc.gov

Dated: February 4, 2000.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Control and Prevention

(CDC).

[FR Doc. 00–3062 Filed 2–9–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–2250]

Agency Information Collection

Activities; Announcement of OMB

Approval; Current Good Manufacturing

Practices for Blood and Blood

Components; Notification of

Consignees Receiving Blood and

Blood Components at Increased Risk

for Transmitting HIV Infection

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘Current Good Manufacturing Practices

for Blood and Blood Components;

Notification of Consignees Receiving

Blood and Blood Components at

Increased Risk for Transmitting HIV

Infection’’ has been approved by the

Office of Management and Budget

(OMB) under the Paperwork Reduction

Act of 1995.

FOR FURTHER INFORMATION CONTACT:

JonnaLynn P. Capezzuto, Office of

Information Resources Management

(HFA–250), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–827–4659.

SUPPLEMENTARY INFORMATION: In the

Federal Register of November 4, 1999

(64 FR 60212), the agency announced

that the proposed information collection

had been submitted to OMB for review

and clearance under 44 U.S.C. 3507. An

agency may not conduct or sponsor, and

a person is not required to respond to,

a collection of information unless it

displays a currently valid OMB control

number. OMB has now approved the

information collection and has assigned

OMB control number 0910–0336. The

approval expires on January 31, 2003. A

copy of the supporting statement for this

information collection is available on

the Internet at http://www.fda.gov/

ohrms/dockets.

Dated: February 3, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

[FR Doc. 00–3013 Filed 2–9–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 99N–0407]

Agency Information Collection

Activities; Announcement of OMB

Approval; Reclassification Petitions for

Medical Devices

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘Reclassification Petitions for Medical

Devices’’ has been approved by the

Office of Management and Budget

(OMB) under the Paperwork Reduction

Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Peggy Schlosburg, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1223.

SUPPLEMENTARY INFORMATION: In the

Federal Register of December 10, 1999

(64 FR 69270), the agency announced

that the proposed information collection

had been submitted to OMB for review

and clearance under 44 U.S.C. 3507. An

agency may not conduct or sponsor, and

a person is not required to respond to,

a collection of information unless it

displays a currently valid OMB control

number. OMB has now approved the

information collection and has assigned

OMB control number 0910–0138. The

approval expires on January 31, 2003. A

copy of the supporting statement for this

information collection is available on

the Internet at http://www.fda.gov/

ohrms/dockets.

Dated: February 3, 2000.

William K. Hubbard,

Senior Associate Commissioner for Policy,

Planning, and Legislation.

[FR Doc. 00–3015 Filed 2–9–00; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

Nonclinical Studies Subcommittee of

the Advisory Committee for

Pharmaceutical Science; Notice of

Meeting

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

This notice announces a forthcoming

meeting of a public advisory committee

of the Food and Drug Administration

(FDA). The meeting will be open to the

public.

Name of Committee: Nonclinical Studies

Subcommittee of the Advisory Committee for

Pharmaceutical Science (formerly the

Generic Drugs Advisory Committee).

General Function of the Committee: To

provide advice and recommendations to the

agency on FDA regulatory issues.

Date and Time: The meeting will be held

on March 9, 2000, 8:30 a.m. to 5:30 p.m.

Location: Center for Drug Evaluation and

Research conference room 1066, 5630 Fishers

Lane, Rockville, MD.

Contact Person: Kimberly L. Topper,

Center for Drug Evaluation and Research

(HFD–21), Food and Drug Administration,

5600 Fishers Lane Rockville, MD 20857, 301–

827–7001, e-mail: TOPPERK@cder.fda.gov, or

FDA Advisory Committee Information Line,

1–800–741–8138 (301–443–0572 in the

Washington, DC area), code 12539. Please

call the Information Line for up-to-date

information on this meeting.

Agenda: The subcommittee meeting will

discuss collaborative approaches to scientific

research issues of common interest to the

pharmaceutical industry, universities, the

public, and FDA. Specific areas of focus will

be in the nonclinical studies areas of: (1)

Interspecies biomarkers of toxicity and (2)

noninvasive imaging.

Procedure: Interested persons may present

data, information, or views, orally or in

writing, on issues pending before the

committee. Written submissions may be

made to the contact person by February 25,

2000. Oral presentations from the public will

be scheduled between approximately 1 p.m.

to 2 p.m. Time allotted for each presentation

may be limited. Those desiring to make

formal oral presentations should notify the

contact person before February 25, 2000, and